AU1777201A - Novel methods of diagnosing and determining prognosis of breast cancer, compositions, and methods of screening for breast cancer modulators - Google Patents

Novel methods of diagnosing and determining prognosis of breast cancer, compositions, and methods of screening for breast cancer modulators

Info

Publication number
AU1777201A
AU1777201A AU17772/01A AU1777201A AU1777201A AU 1777201 A AU1777201 A AU 1777201A AU 17772/01 A AU17772/01 A AU 17772/01A AU 1777201 A AU1777201 A AU 1777201A AU 1777201 A AU1777201 A AU 1777201A
Authority
AU
Australia
Prior art keywords
breast cancer
methods
diagnosing
screening
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17772/01A
Inventor
Kurt C. Gish
David Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Publication of AU1777201A publication Critical patent/AU1777201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU17772/01A 1999-11-16 2000-11-16 Novel methods of diagnosing and determining prognosis of breast cancer, compositions, and methods of screening for breast cancer modulators Abandoned AU1777201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44067699A 1999-11-16 1999-11-16
US09440676 1999-11-16
PCT/US2000/031736 WO2001035811A2 (en) 1999-11-16 2000-11-16 Methods of diagnosing and determining prognosis of breast cancer

Publications (1)

Publication Number Publication Date
AU1777201A true AU1777201A (en) 2001-05-30

Family

ID=23749724

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17772/01A Abandoned AU1777201A (en) 1999-11-16 2000-11-16 Novel methods of diagnosing and determining prognosis of breast cancer, compositions, and methods of screening for breast cancer modulators

Country Status (2)

Country Link
AU (1) AU1777201A (en)
WO (1) WO2001035811A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939824B1 (en) * 1996-10-31 2007-06-06 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2308029A1 (en) * 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6410507B1 (en) * 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU3752700A (en) * 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
JP2004503208A (en) * 2000-02-29 2004-02-05 アボット・ラボラトリーズ Reagents and methods useful for detecting breast disease
ATE353974T1 (en) * 2000-04-03 2007-03-15 Corixa Corp METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
WO2001098339A2 (en) * 2000-06-22 2001-12-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer

Also Published As

Publication number Publication date
WO2001035811A3 (en) 2002-09-12
WO2001035811A2 (en) 2001-05-25
WO2001035811A9 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
EP1090291A4 (en) Method for early diagnosis of, and determination of prognosis in, cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU4229899A (en) Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
AU4085097A (en) Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
AU3105700A (en) Methods for detection of antiestrogen-resistant breast cancer
AU6468998A (en) Compositions and method for the early diagnosis of ovarian cancer
AU6902200A (en) Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002342004A1 (en) Methods and compositions for detecting colon cancers
AU1465801A (en) Methods for cancer prognosis and diagnosis
EP1144632A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU5781800A (en) Methods and compositions for assaying analytes
AU8259798A (en) Method for detection of breast cancer
AU2002258597A1 (en) Prognostic methods for breast cancer
HK1040283A1 (en) Screening test for early detection of colorectal cancer
AU4150999A (en) Method and kit for early diagnosis of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase